Home › Funds › Patient Square Capital LP › ELVN
Patient Square Capital LP position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
Patient Square Capital LP reported holding 212,500 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$9.7M, representing 1.55% of its reported portfolio and ranking #17 among its reported holdings. Patient Square Capital LP has disclosed ELVN holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's ELVN position evolved
Patient Square Capital LP first disclosed a stake in ELVN in Q3 2024 at 90,572 shares (US$2.3M). The position peaked in Q2 2026 at 212,500 shares, worth US$10.8M. Across 9 filings, Patient Square Capital LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 212,500 shares valued at US$9.7M. Notable position changes include a 147% increase in Q4 2024 (shares fell 13% over the following quarter), a 35% trim in Q1 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 90.57K | $2.31M | New |
| Q4 2024 | 224.04K | $5.04M | Add |
| Q1 2025 | 253.84K | $5.00M | Add |
| Q2 2025 | 245.84K | $4.93M | Reduce |
| Q3 2025 | 250.84K | $5.13M | Add |
| Q4 2025 | 308.14K | $4.75M | Add |
| Q1 2026 | 200.00K | $7.84M | Reduce |
| Q2 2026 | 212.50K | $10.78M | Add |
| Q3 2026 | 212.50K | $9.74M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $326.35M · Q2 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- First Turn Management, LLC 954.36K sh · $48.43M · Q2 2026
- SAMLYN CAPITAL, LLC 912.64K sh · $46.32M · Q2 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held ELVN?
Patient Square Capital LP has disclosed ELVN holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Patient Square Capital LP's current position in ELVN?
As of Q3 2026, Patient Square Capital LP holds 212.50K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $9.74M, representing 1.55% of its reported portfolio and ranking #17.
Has Patient Square Capital LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Patient Square Capital LP held unchanged its position in ELVN. The position peaked in Q2 2026 at 212.50K shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.